NASDAQ
Adaptimmune Therapeutics plc (ADAP) has a current ratio of 2.92x as of Monday, May 25, 2026. This represents a 50.67% decrease compared to its 12-month average of 5.91x. The current ratio measures a company's ability to cover short-term obligations by comparing current assets to current liabilities.
No price data available for this timeframe.